Clinical Trial Update: Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Treatment of Chronic Hepatitis B Virus (HBV) Infection [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated adding TQA3605 to nucleoside analogs for chronic hepatitis B virus infection with low-level viremia; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Nucleoside analogs (nucleoside analogs)
• TQA3605

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: HBV Infection With LLV | Phase 2 | Status: COMPLETED